Global Information
회사소개 | 문의 | 비교리스트

세계의 신장암 치료와 진단 시장 예측(2019-2028년)

Global Kidney Cancer Therapeutics and Diagnostics Market Forecast 2019-2028

리서치사 Inkwood Research
발행일 2020년 09월 상품 코드 956656
페이지 정보 영문 224 Pages
가격
US $ 2,500 ₩ 2,954,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 되지 않으며, 인쇄 또한 불가능합니다.
US $ 3,000 ₩ 3,545,000 PDF (Multi User License) help
동일 사업장(소재지) 내 5명까지 이용가능한 라이센스입니다. PDF 파일은 Copy & Paste가 되지 않습니다. 인쇄는 1명당 1회에 한해 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,318,000 PDF (Enterprisewide License) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 신장암 치료와 진단 시장 예측(2019-2028년) Global Kidney Cancer Therapeutics and Diagnostics Market Forecast 2019-2028
발행일 : 2020년 09월 페이지 정보 : 영문 224 Pages

세계의 신장암 치료와 진단 시장 규모는 2019-2028년 5.52%의 CAGR로 계속 성장할 것으로 예측됩니다. 시장 확대의 원동력은 저침습 프로세스의 이용 확대, 조사 개발비의 증가, 신장암 환자의 증가 등의 요인입니다.

조기진단의 보급 확대에 따라 암 유병률이 증가하고 있으며, 2020년에는 세계에서 신장암의 증례가 22% 증가할 것이라는 예측도 있습니다. 신장암은 몇가지 합병증과 관련되어 있으므로 조기 진단과 치료가 필요합니다. 액체생검을 비롯한 최근의 기술적인 진보는 신장암 진단의 수요를 촉진할 것으로 보입니다.

세계의 신장암 치료와 진단 시장을 조사했으며, 시장 역학, 암 유형별, 컴포넌트별, 지역별 분석, 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 조사 범위와 조사 방법

  • 조사 목적
  • 조사 범위
  • 조사 방법
  • 전제와 제한

제2장 개요

  • 시장 규모 추산
  • 시장 개요

제3장 시장 역학

  • 시장의 정의
  • 주요 성장 촉진요인
    • 신장암 증례의 증가 동향
    • 최소 침습적 프로세스의 이용 확대
    • 연구개발비의 증가
  • 주요 제약
    • 신장암 치료와 진단의 고액의 비용
    • 신장암 치료제의 임상시험에서 낮은 성공률
    • 엄격한 규제

제4장 주요 분석 결과

  • Porter의 산업 분석
  • COVID-19의 영향
  • 시장 기회 매트릭스
  • 벤더 각사의 세력도
  • 투자에 관한 주요 인사이트

제5장 암 유형별 시장

  • 투명세포 RCC
  • 유두 RCC
  • 혐색소세포 RCC
  • 요로 상피암/이행상피암
  • 기타

제6장 컴포넌트별 시장

  • 의약품
    • 치료 클래스별 의약품
    • 약리 클래스별 의약품
  • 진단
    • 영상 검사
    • 생검법
    • 혈액검사
    • 기타

제7장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 러시아
    • 벨기에
    • 폴란드
    • 기타
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주와 뉴질랜드
    • 태국
    • 인도네시아
    • 베트남
    • 기타
  • 기타 지역
    • 라틴아메리카
    • 중동·아프리카

제8장 기업 개요

  • ABBOTT LABORATORIES
  • AMGEN INC
  • BAYER AG
  • BECTON, DICKINSON AND COMPANY(BD)
  • BRISTOL-MYERS SQUIBB COMPANY
  • EXELIXIS
  • F. HOFFMANN-LA ROCHE
  • MERCK & CO INC
  • MERCK KGAA
  • NOVARTIS INTERNATIONAL AG
  • NXSTAGE MEDICAL INC
  • PFIZER INC
  • SEATTLE GENETIC
KSA 20.09.14

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
  • TABLE 2: RISK FACTORS DEVELOPING KIDNEY CANCER
  • TABLE 3: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 4: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL CLEAR CELL RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 6: GLOBAL CLEAR CELL RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL PAPILLARY RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 8: GLOBAL PAPILLARY RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL CHROMOPHOBE RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 10: GLOBAL CHROMOPHOBE RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 11: GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 12: GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 13: GLOBAL OTHER KIDNEY CANCERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 14: GLOBAL OTHER KIDNEY CANCERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 16: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 18: GLOBAL DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 20: GLOBAL THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 21: GLOBAL TARGETED THERAPY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 22: GLOBAL TARGETED THERAPY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 23: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 24: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 25: GLOBAL OTHER THERAPEUTIC CLASS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 26: GLOBAL OTHER THERAPEUTIC CLASS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 27: GLOBAL PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 28: GLOBAL PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 29: GLOBAL ANGIOGENESIS INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 30: GLOBAL ANGIOGENESIS INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 31: GLOBAL MTOR INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 32: GLOBAL MTOR INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 33: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 34: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 35: GLOBAL CYTOKINE IMMUNOTHERAPY (IL-2) MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 36: GLOBAL CYTOKINE IMMUNOTHERAPY (IL-2) MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 37: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 38: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 39: GLOBAL DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 40: GLOBAL DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 41: GLOBAL IMAGING TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 42: GLOBAL IMAGING TEST MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 43: GLOBAL BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 44: GLOBAL BIOPSY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 45: GLOBAL BLOOD TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 46: GLOBAL BLOOD TEST MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 47: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 48: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 49: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 50: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 51: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 52: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 53: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 54: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 55: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 56: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 57: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 58: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, IN 2019
  • FIGURE 5: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CLEAR CELL RCC, 2019-2028 (IN $ MILLION)
  • FIGURE 6: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY PAPILLARY RCC, 2019-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CHROMOPHOBE RCC, 2019-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA, 2019-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY OTHER KIDNEY CANCERS, 2019-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, IN 2019
  • FIGURE 11: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUGS, 2019-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL THERAPEUTIC DRUG CLASS MARKET, BY TARGETED THERAPY, 2019-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL THERAPEUTIC DRUG CLASS MARKET, BY IMMUNOTHERAPY, 2019-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL THERAPEUTIC DRUG CLASS MARKET, BY OTHER THERAPEUTIC CLASS, 2019-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL PHARMACOLOGIC CLASS MARKET, BY ANGIOGENESIS INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL PHARMACOLOGIC CLASS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL PHARMACOLOGIC CLASS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL PHARMACOLOGIC CLASS MARKET, BY CYTOKINE IMMUNOTHERAPY (IL-2), 2019-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2019-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL DIAGNOSTICS MARKET, BY IMAGING TEST, 2019-2028 (IN $ MILLION)
  • FIGURE 21: GLOBAL DIAGNOSTICS MARKET, BY BIOPSY, 2019-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL DIAGNOSTICS MARKET, BY BLOOD TEST, 2019-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2019-2028 (IN $ MILLION)
  • FIGURE 24: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 25: THE UNITED STATES KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 26: CANADA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 27: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 28: GERMANY KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 29: THE UNITED KINGDOM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 30: FRANCE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 31: ITALY KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 32: RUSSIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 33: BELGIUM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 34: POLAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 35: REST OF EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 36: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 37: CHINA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 38: JAPAN KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 39: INDIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 40: SOUTH KOREA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 41: AUSTRALIA & NEW ZEALAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 42: THAILAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 43: INDONESIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 44: VIETNAM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 45: REST OF ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 46: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 47: LATIN AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 48: MIDDLE EAST & AFRICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

KEY FINDINGS

The global kidney cancer therapeutics and diagnostics market is projected to register a CAGR of 5.52% during the forecast period, 2019-2028. The factors propelling the growth of the market are estimated to be the rising usage of minimally invasive processes, increasing research & development expenditure, and the growing prevalence of kidney cancer cases.

MARKET INSIGHTS

There is an increasing prevalence of cancer, along with the rising adoption of early diagnosis. Some estimations suggest that there will be a 22% increase in kidney cases across the globe in 2020. It is necessary to diagnose and treat kidney cancer at the earliest, since it is associated with several comorbidities. Recent advancements like the liquid biopsy technique are projected to result in healthy demand for kidney cancer diagnosis.

There is an emphasis on using minimally-invasive techniques in surgical procedures. There has been an increase in the use of the minimally-invasive catheter-based endovascular procedure to regulate hypertension. This has resulted in the growing adoption of kidney cancer treatment devices. These devices reduce cardiometabolic risks. They also aid in minimizing hospital stay, since the procedure and the necessary processes do not take more than six hours. This restricts direct and indirect hospitalization costs. Thus, rising minimally-invasive processes drive market growth. However, the high costs associated with the treatment and diagnosis, are projected to restrain the market growth.

REGIONAL INSIGHTS

The analysis of the geographical division of the global kidney cancer therapeutics and diagnostics market includes the assessment of Asia Pacific, Europe, North America, and the rest of the world. North America dominated the global market in 2019. The well-developed healthcare infrastructure and the presence of major companies are influencing the market growth prospects of the region.

COMPETITIVE INSIGHTS

As per estimations, there will be intense competition between the well-established cancer therapeutics manufacturers. Some of the established players in the market include Bayer AG, Amgen Inc, Abbott Laboratories, Becton, Dickinson and Company (BD), etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING PREVALENCE OF KIDNEY CANCER CASES
    • 3.2.2. INCREASING USAGES OF MINIMALLY INVASIVE PROCESSES
    • 3.2.3. SURGING RESEARCH AND DEVELOPMENT EXPENDITURE
  • 3.3. KEY RESTRAINTS
    • 3.3.1. HIGH COSTS ASSOCIATED WITH THE TREATMENT AND DIAGNOSIS OF KIDNEY CANCER
    • 3.3.2. LOW RATE OF SUCCESS IN THE CLINICAL TRIALS OF KIDNEY CANCER DRUGS
    • 3.3.3. STRINGENT REGULATIONS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. IMPACT OF COVID-19 ON KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHT

5. MARKET BY CANCER TYPE

  • 5.1. CLEAR CELL RCC
  • 5.2. PAPILLARY RCC
  • 5.3. CHROMOPHOBE RCC
  • 5.4. UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
  • 5.5. OTHER KIDNEY CANCERS

6. MARKET BY COMPONENT

  • 6.1. DRUGS
    • 6.1.1. DRUGS BY THERAPEUTIC CLASS
      • 6.1.1.1. TARGETED THERAPY
      • 6.1.1.2. IMMUNOTHERAPY
      • 6.1.1.3. OTHER THERAPEUTIC CLASS
    • 6.1.2. DRUGS BY PHARMACOLOGIC CLASS
      • 6.1.2.1. ANGIOGENESIS INHIBITORS
      • 6.1.2.2. MTOR INHIBITORS
      • 6.1.2.3. MONOCLONAL ANTIBODIES
      • 6.1.2.4. CYTOKINE IMMUNOTHERAPY (IL-2)
  • 6.2. DIAGNOSTICS
    • 6.2.1. IMAGING TEST
    • 6.2.2. BIOPSY
    • 6.2.3. BLOOD TEST
    • 6.2.4. OTHER DIAGNOSTICS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. GERMANY
    • 7.2.2. THE UNITED KINGDOM
    • 7.2.3. FRANCE
    • 7.2.4. ITALY
    • 7.2.5. RUSSIA
    • 7.2.6. BELGIUM
    • 7.2.7. POLAND
    • 7.2.8. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. JAPAN
    • 7.3.3. INDIA
    • 7.3.4. SOUTH KOREA
    • 7.3.5. AUSTRALIA & NEW ZEALAND
    • 7.3.6. THAILAND
    • 7.3.7. INDONESIA
    • 7.3.8. VIETNAM
    • 7.3.9. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST & AFRICA

8. COMPANY PROFILES

  • 8.1. ABBOTT LABORATORIES
  • 8.2. AMGEN INC
  • 8.3. BAYER AG
  • 8.4. BECTON, DICKINSON AND COMPANY (BD)
  • 8.5. BRISTOL-MYERS SQUIBB COMPANY
  • 8.6. EXELIXIS
  • 8.7. F. HOFFMANN-LA ROCHE
  • 8.8. MERCK & CO INC
  • 8.9. MERCK KGAA
  • 8.10. NOVARTIS INTERNATIONAL AG
  • 8.11. NXSTAGE MEDICAL INC
  • 8.12. PFIZER INC
  • 8.13. SEATTLE GENETIC
Back to Top
전화 문의
F A Q